CBMG 2017 Investor Presentation - CAR-T Cell Therapy

NASDAQ-listed China Biologic Products is a biomedical innovator focused on immuno-oncology and degenerative disease treatments through proprietary CAR-T and allogeneic stem cell therapies. The company operates cutting-edge R&D and GMP manufacturing facilities with capacity to serve up to 10,000 patients annually in each therapy category, addressing a large addressable market in China with 5M annual cancer patients and 57M osteoarthritis patients.